Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Syrrx’s Structural Proteomics At Heart Of Pharmacia Alliance

Jan. 25, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

Enzon, Inhale Enter Broad Deal On Pegylation, Licensing, Lawsuit

Jan. 9, 2002

By Aaron Lorenzo

View All Articles by Aaron Lorenzo